The laminin β1-competing peptide YIGSR induces a hypercontractile, hypoproliferative airway smooth muscle phenotype in an animal model of allergic asthma
© Dekkers et al. 2010
Received: 27 July 2010
Accepted: 3 December 2010
Published: 3 December 2010
Fibroproliferative airway remodelling, including increased airway smooth muscle (ASM) mass and contractility, contributes to airway hyperresponsiveness in asthma. In vitro studies have shown that maturation of ASM cells to a (hyper)contractile phenotype is dependent on laminin, which can be inhibited by the laminin-competing peptide Tyr-Ile-Gly-Ser-Arg (YIGSR). The role of laminins in ASM remodelling in chronic asthma in vivo, however, has not yet been established.
Using an established guinea pig model of allergic asthma, we investigated the effects of topical treatment of the airways with YIGSR on features of airway remodelling induced by repeated allergen challenge, including ASM hyperplasia and hypercontractility, inflammation and fibrosis. Human ASM cells were used to investigate the direct effects of YIGSR on ASM proliferation in vitro.
Topical administration of YIGSR attenuated allergen-induced ASM hyperplasia and pulmonary expression of the proliferative marker proliferating cell nuclear antigen (PCNA). Treatment with YIGSR also increased both the expression of sm-MHC and ASM contractility in saline- and allergen-challenged animals; this suggests that treatment with the laminin-competing peptide YIGSR mimics rather than inhibits laminin function in vivo. In addition, treatment with YIGSR increased allergen-induced fibrosis and submucosal eosinophilia. Immobilized YIGSR concentration-dependently reduced PDGF-induced proliferation of cultured ASM to a similar extent as laminin-coated culture plates. Notably, the effects of both immobilized YIGSR and laminin were antagonized by soluble YIGSR.
These results indicate that the laminin-competing peptide YIGSR promotes a contractile, hypoproliferative ASM phenotype in vivo, an effect that appears to be linked to the microenvironment in which the cells are exposed to the peptide.
Airway inflammation, airway obstructive reactions and development of transient airway hyperresponsiveness are primary features of acute asthma [1, 2]. In addition, structural changes in the airway wall are thought to contribute to a decline of lung function and development of persistent airway hyperresponsiveness in chronic asthma [1, 3]. These structural changes include goblet cell metaplasia and mucous gland hyperplasia, increased vascularity, altered deposition of the extracellular matrix (ECM) proteins and accumulation of contractile airway smooth muscle (ASM) cells [1, 4–7]. ASM cells can contribute to airway remodelling as they retain the ability for reversible phenotypic switching, enabling them to exhibit variable contractile, proliferative, migratory and synthetic states [8, 9]. In vitro, modulation to a proliferative phenotype results from exposure of ASM cells to mitogenic stimuli, leading to increased proliferative activity and decreased contractile function [10–12]. Removal of growth factors, for example by serum deprivation in the presence of insulin, results in maturation of the cells to a contractile phenotype, characterized by increased expression of contractile protein markers, increased contractile function and increased expression of laminin α2, β1 and γ1 chains [8, 13–15].
Laminins are basement membrane ECM components composed of heterotrimers of α, β and γ chains. Five laminin α-, three β- and three γ-chains have been identified in mammals, which form at least fifteen different laminin isoforms . Various laminin chains are expressed in the lung and expression appears to be tissue- and developmental stage-dependent . In adult asthmatics, expression of laminin α2 and β2 chains in the airways is increased [18, 19]. In addition, asthmatics with compromised epithelial integrity show increased laminin γ2 chain expression in the airways .
Laminins appear to be essential for lung development and are important determinants of ASM function. Laminin α1 and α2 chains are required for pulmonary branching and differentiation of naïve mesenchymal cells into ASM [16, 20, 21]. Primary ASM cells cultured on laminin-111 (laminin-1) are retained in a hypoproliferative phenotype, associated with high expression levels of contractile proteins . This is of functional relevance as the induction of a hypocontractile ASM phenotype by PDGF can be prevented by co-incubation with laminin-111 . Increased expression of endogenous laminin-211 (laminin-2) is essential for ASM cell maturation , and studies from our laboratory show that laminin-211 is essential for the induction of a hypercontractile, hypoproliferative ASM phenotype by prolonged insulin exposure .
Recently, in an animal model of chronic allergic asthma we showed that ASM remodelling can be inhibited by the integrin-blocking peptide Arg-Gly-Asp-Ser (RGDS) , which contains the RGD-binding motif present in ECM proteins like fibronectin, collagens and laminins [24, 25]. The specific role of laminins in ASM remodelling in vivo, however, remains to be determined. Therefore, using a guinea pig model of chronic asthma, we explored the role of laminins in ASM remodelling in vivo, by treating the animals with the specific soluble laminin-competing peptide Tyr-Ile-Gly-Ser-Arg (YIGSR), a binding motif present in the β1 chain of laminins .
All protocols described in this study were approved by the University of Groningen Committee for Animal Experimentation. Outbred, male, specified pathogen-free Dunkin Hartley guinea pigs (Harlan, Heathfield, UK) weighing 150-250 g were sensitized to ovalbumin (Sigma Chemical Co., St. Louis, MO, USA), using Al(OH)3 as adjuvant, as described previously . In short, 0.5 ml of an allergen solution containing 100 μg/ml ovalbumin and 100 mg/ml Al(OH)3 in saline was injected intraperitoneally, while another 0.5 ml was divided over seven intracutaneous injection sites in the proximity of lymph nodes in the paws, lumbar regions and the neck. The animals were group-housed in cages in climate controlled animal quarters and given water and food ad libitum, while a 12-hour on/12-hour off light cycle was maintained.
Four weeks after sensitization, allergen-provocations were performed by inhalation of aerosolized solutions of saline (control) or ovalbumin as described previously . Aerosols were produced by a DeVilbiss nebulizer (type 646, DeVilbiss, Somerset, PA, USA). Provocations were carried out in a specially designed Perspex cage (internal volume 9 L), in which the guinea pigs could move freely. Before the start of the experimental protocol, the animals were habituated to the provocation procedures. After an adaptation period of 30 min, three consecutive provocations with saline were performed, each provocation lasting 3 min, separated by 7 min intervals. Ovalbumin challenges were performed by inhalation of increasing concentrations of ovalbumin (0.5, 1.0, or 3.0 mg/ml) in saline. Allergen inhalations were discontinued when the first signs of respiratory distress were observed. No anti-histaminic was needed to prevent the development of anaphylactic shock.
Guinea pigs were challenged with either saline or ovalbumin once weekly for 12 consecutive weeks, as described previously [23, 28, 29]. Animals were treated with saline or YIGSR (Calbiochem, Nottingham, UK) by intranasal instillation (2.5 mM, 200 μl), 0.5 hr prior to and 5.5 hr after each challenge with saline or ovalbumin, as described previously for RGDS . Treatment groups were as follows: saline-treated, saline-challenged controls (n = 6); YIGSR-treated, saline-challenged animals (n = 5); saline-treated, ovalbumin-challenged animals (n = 7) and YIGSR-treated, ovalbumin-challenged animals (n = 7). Data for the saline-treated animals (controls) have been published previously as part of a simultaneous parallel study . During the 12-week challenge protocol, guinea pig weight was monitored weekly and no differences in weight gain between different treatment groups were found
Guinea pigs were sacrificed by experimental concussion, followed by rapid exsanguination 24 h after the last challenge. The lungs were immediately resected and kept on ice for further processing. The trachea was removed and transferred to a Krebs-Henseleit (KH) buffer of the following composition (mM): 117.5 NaCl, 5.60 KCl, 1.18 MgSO4, 2.50 CaCl2, 1.28 NaH2PO4, 25.00 NaHCO3, and 5.50 glucose, pregassed with 5% CO2 and 95% O2, pH 7.4 at 37°C. Lungs were divided into three parts and weighed. One part was snap frozen in liquid nitrogen for the measurement of hydroxyproline content. One part was frozen at -80°C in isopentane and stored at -80°C for histological purposes. The remaining part was snap frozen in liquid nitrogen and stored at -80°C to be used for Western analysis.
Isometric tension measurements
Isometric contraction experiments were performed as described previously [23, 28, 29]. Briefly, the trachea was prepared free of connective tissue. Single open-ring, epithelium-denuded preparations were mounted for isometric recording in organ baths, containing KH buffer at 37°C, continuously gassed with 5% CO2 and 95% O2, pH 7.4. During a 90-min equilibration period, resting tension was gradually adjusted to 0.5 g. Subsequently, muscle strips were precontracted with 20 mM and 40 mM KCl. Following washouts, maximal relaxation was established by the addition of 0.1 μM (-)-isoproterenol (Sigma). After washout and another 30 min equilibration period, cumulative concentration-response curves were constructed using stepwise increasing concentrations of KCl (5.6-50 mM) or methacholine (1 nM - 0.1 mM). When maximal tension was reached, the strips were washed several times and maximal relaxation was established using 10 μM (-)-isoproterenol.
Immunohistochemistry was performed as described previously [23, 28, 29]. Transverse cross-sections (8 μm) of the main bronchi from both right and left lung lobes were used for morphometric analyses. To identify smooth muscle, the sections were stained for smooth-muscle-specific myosin heavy chain (sm-MHC). Sections were dried, fixed with acetone and washed in phosphate-buffered saline (PBS). Subsequently, sections were incubated for 1 h in PBS supplemented with 1% bovine serum albumin (BSA, Sigma) and anti-sm-MHC (diluted 1:100, Neomarkers, Fremont, CA, USA) at room temperature. Sections were then washed with PBS, after which endogenous peroxidase activity was blocked by treatment with PBS containing 0.075% H2O2 for 30 min. Sections were washed with PBS, after which the horseradish peroxidase (HRP)-linked secondary antibody (rabbit anti-mouse IgG, Sigma, diluted 1:200) was applied for 30 min at room temperature. After another three washes, sections were incubated with diaminobenzidine (1 mg/ml) for 5 min in the dark, after which sections were washed and stained with haematoxylin. After rinsing with water the sections were embedded in Kaisers glycerol gelatin. Airways within sections were digitally photographed and subclassified as cartilaginous or non-cartilaginous. All immunohistochemical measurements were carried out digitally, using quantification software (ImageJ). For this purpose, digital photographs of lung sections were analyzed at a magnification of 40-100×. For both types of airways, sm-MHC positive areas were measured by a single observer in a blinded fashion. In addition, haematoxylin-stained nuclei within the ASM bundle were counted. Of each animal, 4 lung sections were prepared per immunohistochemical staining, in which a total of 4 to 5 airways of each classification were analyzed. Eosinophils were identified in haematoxylin-and-eosin-stained lung sections.
Lung homogenates were prepared as described previously [23, 28, 29]. Equal amounts of protein were subjected to electrophoresis and transferred onto nitrocellulose membranes, followed by immunoblotting for sm-MHC and PCNA (Neomarkers), using standard techniques. Antibodies were visualized on film using enhanced chemiluminescence reagents (Pierce, Rockford, IL, USA) and analyzed by densitometry (Totallab™, Nonlinear dynamics, Newcastle, UK). All bands were normalized to β-actin expression.
Lungs were analyzed for hydroxyproline, an estimate of collagen content, as described previously . In short, total lung homogenates were prepared by pulverizing tissue under liquid nitrogen and sonification in PBS. Homogenates were incubated with 1,25 ml 5% trichloroacetic acid on ice for 20 min, after which the samples were centrifuged. The pellet was resuspended in 12 N hydrochloric acid (10 ml) and heated overnight at 110°C. The samples were dissolved in 2 ml water by incubating for 72 h at room temperature. To determine hydroxyproline concentrations, samples were incubated with 100 μl chloramine T (1.4% chloramine T in 0.5 M sodium acetate/10% isopropanol) for 30 min at room temperature. Next, 100 μl Ehrlich's solution (1.0 M 4-dimethylaminobenzaldehyde in 70% isopropanol/30% perchloric acid) was added and samples were incubated at 65°C for 30 min. Samples were cooled to room temperature and hydroxyproline concentrations were quantified by colorimetric measurement (550 nm, Biorad 680 plate reader).
Three human bronchial smooth muscle cell lines, immortalized by stable expression of human telomerase reverse transcriptase (hTERT), were used for all experiments. The primary cells used to generate each cell line were prepared as we have described [30–32]. All procedures were approved by the Human Research Ethics Board of the University of Manitoba. For all experiments, passages 26-34 myocytes grown on uncoated plastic dishes in Dulbecco's Modified Eagle's Medium (DMEM, Gibco BRL Life Technologies, Paisley, U.K.) supplemented with 50 U/ml streptomycin, 50 μg/ml penicillin, (Gibco) and 10% vol/vol Foetal Bovine Serum (FBS, Gibco) were used.
Coating of culture plates with laminin and integrin-blocking peptides
Dilutions of mouse Engelberth-Holm-Swarm (EHS) laminin-111 (10 μg/ml, Invitrogen, Grand Island, NY, USA), YIGSR (1-100 μM), Arg-Gly-Asp-Ser (RGDS, 100 μM, Calbiochem) and Gly-Arg-Ala-Asp-Ser-Pro (GRADSP, 100 μM, Calbiochem) were prepared in PBS and absorbed to 24-well culture plates overnight. Unoccupied protein-binding sites were blocked by a 30-min incubation with 0.1% BSA in PBS. Subsequently, plates were washed twice with plain DMEM and dried before further use.
Cells in DMEM supplemented with streptomycin, penicillin and 10% FBS were plated on uncoated or coated 24-well culture plates at a density of 20,000 cells per well and allowed to attach overnight. Subsequently, cells were maintained in serum-free DMEM supplemented with antibiotics and 1% ITS (Insulin, Transferrin and Selenium, Gibco) for 3 days. Cells were then incubated with or without PDGF-AB (10 ng/ml, human, Bachem, Weil am Rhein, Germany) for 28 h, the last 24 h in the presence of [methyl-3H]-thymidine (0.25 μCi/ml) in DMEM supplemented with antibiotics. After incubation, the cells were washed twice with 0.5 ml PBS at room temperature. Subsequently, the cells were treated with 0.5 ml ice-cold 5% trichloroacetic acid on ice for 30 min, and the acid-insoluble fraction was dissolved in 1 ml NaOH (1 M). Incorporated [3H]-thymidine was quantified by liquid-scintillation counting using a Beckman LS1701 β-counter.
All data represent means ± SEM from n separate experiments. Statistical significance of differences was evaluated using one-way ANOVA, followed by a Newman-Keuls multiple comparisons test. Differences were considered to be statistically significant when P < 0.05.
The laminin β1-competing peptide YIGSR inhibits allergen-induced ASM accumulation in a guinea pig model of chronic allergic asthma
To determine whether the changes in ASM content were associated with changes in cell number and/or cell size, the number of nuclei within the ASM layer were counted and expressed relative to total ASM area. Repeated ovalbumin challenge did not change the number of nuclei per mm2 of smooth muscle area (Figure 1B), indicating that the cell size is unchanged and ovalbumin-induced increases in ASM mass were caused by increased cell number (hyperplasia). YIGSR treatment did not change ASM cell size in saline-challenged animals; however, a small, but significant (P < 0.05) decrease in the number of nuclei/mm2 was observed in ovalbumin-challenged animals (Figure 1B), suggesting that this treatment may lead to some increase in cell size (hypertrophy).
To assess whether the changes in ASM area were associated with changes in proliferative responses, immunoblotting was used to determine expression of the proliferation marker, PCNA, in whole lung homogenates. After repeated ovalbumin-challenge, a considerable increase (4.2 ± 0.2-fold, P < 0.001) in PCNA was observed compared to saline-treated, saline-challenged controls (Figure 1C). Treatment with YIGSR fully normalized the ovalbumin-induced increase in PCNA, when compared to saline-challenged controls (P < 0.001). In the saline-challenged animals, no significant effect of YIGSR treatment on PCNA expression was observed. Unfortunately, specific characterization of the proliferating cells in guinea pig lung sections by immunohistochemistry was not possible with the antibody used. Collectively, these in vivo data indicate that YIGSR treatment inhibits allergen-induced ASM hyperplasia in association with suppressing proliferative responses of lung cells.
YIGSR treatment increases contractile protein accumulation and ASM contractility
Contractile responses of epithelium-denuded, tracheal smooth muscle preparations after repeated saline or ovalbumin challenge of saline- or YIGSR-treated guinea pigs.
E max (g)
pEC 50 (- log M)
E max (g)
EC 50 (mM)
1.42 ± 0.09
6.55 ± 0.18
1.02 ± 0.06
23.7 ± 0.9
1.84 ± 0.04
6.82 ± 0.13
1.41 ± 0.04*
20.4 ± 2.2
2.33 ± 0.22***
6.28 ± 0.11
1.73 ± 0.13**
23.7 ± 1.2
3.11 ± 0.18***, ###
6.61 ± 0.08
2.12 ± 0.19***,#
24.5 ± 1.1
Effects of YIGSR treatment on allergen-induced airway inflammation
Effects of YIGSR treatment on allergen-induced fibrosis
Immobilized YIGSR inhibits ASM cell proliferation in vitro
To assess the effects of soluble YIGSR on proliferative responses of human ASM, cells were cultured on immobilized laminin-111 (10 μg/ml) or YIGSR (100 μM). Subsequently, cells were stimulated with vehicle or PDGF in the absence or presence of soluble YIGSR. As observed previously [11, 15], we found that culturing on laminin-111 inhibited PDGF-induced DNA-synthesis (by 56 ± 11%, P < 0.05, Figure 5C) and cell number (not shown). This inhibitory effect was fully reversed by soluble YIGSR. Surprisingly, the inhibitory effect of coated YIGSR on PDGF-induced proliferation was also fully normalized by soluble YIGSR. Of note, we have reported previously that this peptide did not affect basal or PDGF-induced proliferative responses in the absence of laminin-111 . Collectively, these results indicate that the effects of the laminin-competing peptide YIGSR on ASM proliferative responses may depend on the peptide microenvironment (i.e. soluble versus immobilized).
In the current study, we demonstrate that treatment with the laminin β1 chain-competing peptide YIGSR promotes the formation of a hypercontractile, hypoproliferative ASM phenotype in an animal model of chronic asthma. Topical application of YIGSR to the airways inhibited ASM hyperplasia induced by repeated allergen challenge. However, ASM contractility and contractile protein expression were increased under basal and allergen-challenged conditions. These results appear to be in contrast to previous in vitro studies, demonstrating that soluble YIGSR inhibits maturation of human ASM cells to a hypercontractile, hypoproliferative ASM phenotype [14, 15].
Accumulation of ASM in the airway wall is a characteristic feature of asthma, which may be due to an increase in cell number (hyperplasia) [37, 38] as well as an increase in cell size (hypertrophy) [37, 39]. This ASM accumulation contributes importantly to increased airway resistance and airway hyperresponsiveness [40, 41]. Switching of the ASM phenotype from a contractile to a proliferative state is thought to contribute to the increased ASM mass in asthma . In support, various mitogenic stimuli, including growth factors and ECM proteins, induce a proliferative ASM phenotype in vitro [10–12], an effect that can be inhibited by culturing the cells on immobilized laminin-111 [11, 22, 23] or endogenously produced laminin-211 . These inhibitory effects can be reversed using soluble YIGSR , a binding motif present in the laminin β1 chain . Similarly, in our study culturing human ASM cells on laminin-111 reduced PDGF-induced proliferation, an effect fully normalized by soluble YIGSR. In contrast to this effect of soluble YIGSR, we also show that immobilized YIGSR concentration-dependently inhibited growth factor-induced myocyte proliferation to the same extent as laminin-111. Interestingly, previous work has also shown a disparate effect of immobilized and soluble YIGSR, with the former promoting attachment of various cells [26, 35, 36] whereas the latter blocked attachment to laminin-111  or matrigel . The effects of immobilized YIGSR peptide are specific, as culturing on RGDS or GRADSP did not alter proliferation. Of note, addition of soluble YIGSR normalized the effects of immobilized YIGSR, an affect consistent with studies using alveolar cells and a laminin α chain peptide (Ser-Ile-Asn-Asn-Asn-Arg, or SINNNR) . Collectively, these findings suggest that the laminin-competing peptide YIGSR may either promote or inhibit ASM proliferative responses, depending on the microenvironment of the peptide. The mechanisms underlying these differential effects are unknown. However, since the anti-mitogenic effects of the peptide are only observed when the peptide is immobilized, we speculate that this may be associated with bridging of the 67 kDa laminin receptor LAMR1 - which has high affinity to the YIGSR motif  - whereas soluble YIGSR may competitively inhibit this type of interaction. Similarly, it has been established that binding of ECM proteins such as fibronectin as a monovalent or multivalent ligand to α5β1 integrin has diverse effects on focal contacts, tyrosine kinase activation and cytoskeletal dynamics . Our data indicate that future studies of the ligation of soluble and immobilized YIGSR peptides to specific cell surface receptors and resulting intracellular signaling events are needed.
In addition to ASM accumulation, increased expression of contractile proteins and ASM contractility, and ECM deposition are features of airway remodelling in asthma . In the airways of asthmatics increased expression of laminin α2 and β2 chains is observed [18, 19], and laminin γ2 chain expression inversely correlates with epithelial integrity . Laminins have not only been shown to inhibit ASM proliferation, but also to be critical in maintenance and induction of a (hyper)contractile ASM phenotype. Indeed, culturing of ASM cells on a laminin-111 matrix inhibits proliferation [11, 22, 23], maintains contractile protein expression in the presence of growth factors , and prevents induction of a hypocontractile phenotype by PDGF . Induction of a contractile ASM phenotype in serum-free culture supplemented with insulin is associated with increased expression of laminin α2, β1 and γ1 chains, all found in the laminin-211 isoform [14, 15]. Importantly, the expression of endogenous laminin is required for phenotype maturation, as soluble YIGSR prevents contractile protein accumulation and hypercontractility [14, 15]. Recently, using our guinea pig model of chronic asthma we showed that treatment with the RGD-containing RGDS peptide largely inhibits ASM hyperplasia and hypercontractility . The RGD sequence exists in several ECM proteins [24, 25], thus the specific contribution of laminins cannot be discerned from these prior studies. In the present study we found that in vivo treatment with YIGSR inhibited allergen-induced ASM hyperplasia, but increased both the expression of sm-MHC and ASM contractility. In addition, a small increase in cell size in the allergen-challenged YIGSR treated animals was observed suggesting that hypertrophy may also have played a role in the observed effects. Collectively, our results indicate that treatment with YIGSR inhibits allergen-induced ASM hyperplasia and increases ASM contractility in vivo, suggesting that YIGSR mimics and/or promotes rather than inhibits laminin function under this condition.
Eosinophils express a number of integrins, of which the α6β1 mediates adhesion to laminin, but not to collagen type I or type IV [45, 46]. Eosinophils isolated from allergic donors show higher adhesion to laminin than those isolated from healthy subjects . Migration of eosinophils through matrigel, a basement membrane extract containing laminin-111, also requires interaction with β1-integrins . These findings suggest that laminin-competing peptides could affect allergen-induced airway infiltration of inflammatory cells. To date no reports on YIGSR effects on eosinophil migration are available. In our study we noted that YIGSR increased allergen-induced eosinophil cell numbers in the submucosal compartment, without affecting eosinophil numbers in the adventitial compartment. The increased number of eosinophils in the submucosa suggests that, rather than, infiltration, retention time of the eosinophils in the compartment could be increased. Importantly, increased ECM deposition may be secondary to prolonged airway inflammation  and therefore increased allergen-induced airway fibrosis in YIGSR-treated animals could also indirectly result from increased eosinophilia. As increased and altered deposition of ECM proteins, including laminins and collagens, is a feature of remodelling in chronic asthma [33, 34] it is important that further investigation focus on understanding the effects of YIGSR and laminins on ECM deposition by fibroblasts and other structural cells.
In summary, our results indicate that the laminin-competing peptide YIGSR promotes a contractile, hypoproliferative ASM phenotype in vivo, an effect that is in striking contrast to current and previously reported evidence showing that soluble YIGSR prevents laminin-dependent phenotype maturation. It appears that the microenvironment of the peptide is a critical determinant of its effect as immobilized YIGSR does mimic the effects of laminin matrix on ASM in vitro. Our data suggest that topically applied YIGSR mimics rather than inhibits the effects of laminin in vivo, and its use is linked to increased allergen-induced fibrosis, submucosal eosinophilia, ASM hyperplasia and airway hypercontractility. These data indicate that strategies to develop capacity to use peptides that target ECM-cell interaction to treat bronchial asthma need to be developed with care, in particular with focus on understanding differences of such interventions that may exist between in vitro and in vivo systems.
This work was financially supported by the Netherlands Asthma Foundation, grant NAF 3.2.03.36. We are grateful to Dr. W.T. Gerthoffer (University of Nevada-Reno) for preparation of the hTERT cell lines used in the study.
- Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000, 161:1720–1745.PubMed
- Cockcroft DW, Davis BE: Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol 2006, 118:551–559.PubMedView Article
- Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST: Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003, 111:215–225.PubMedView Article
- Dunnill MS, Massarella GR, Anderson JA: A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax 1969, 24:176–179.PubMedView Article
- Parameswaran K, Willems-Widyastuti A, Alagappan VK, Radford K, Kranenburg AR, Sharma HS: Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochem Biophys 2006, 44:139–146.PubMedView Article
- Fernandes DJ, Bonacci JV, Stewart AG: Extracellular matrix, integrins, and mesenchymal cell function in the airways. Curr Drug Targets 2006, 7:567–577.PubMedView Article
- Dekkers BG, Maarsingh H, Meurs H, Gosens R: Airway structural components drive airway smooth muscle remodeling in asthma. Proc Am Thorac Soc 2009, 6:683–692.PubMedView Article
- Halayko AJ, Salari H, Ma X, Stephens NL: Markers of airway smooth muscle cell phenotype. Am J Physiol 1996, 270:L1040-L1051.PubMed
- Halayko AJ, Tran T, Ji SY, Yamasaki A, Gosens R: Airway smooth muscle phenotype and function: interactions with current asthma therapies. Curr Drug Targets 2006, 7:525–540.PubMedView Article
- Gosens R, Meurs H, Bromhaar MM, McKay S, Nelemans SA, Zaagsma J: Functional characterization of serum- and growth factor-induced phenotypic changes in intact bovine tracheal smooth muscle. Br J Pharmacol 2002, 137:459–466.PubMedView Article
- Dekkers BG, Schaafsma D, Nelemans SA, Zaagsma J, Meurs H: Extracellular matrix proteins differentially regulate airway smooth muscle phenotype and function. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1405-L1413.PubMedView Article
- Gosens R, Roscioni SS, Dekkers BG, Pera T, Schmidt M, Schaafsma D, Zaagsma J, Meurs H: Pharmacology of airway smooth muscle proliferation. Eur J Pharmacol 2008, 585:385–397.PubMedView Article
- Schaafsma D, McNeill KD, Stelmack GL, Gosens R, Baarsma HA, Dekkers BG, Frohwerk E, Penninks JM, Sharma P, Ens KM, et al.: Insulin increases the expression of contractile phenotypic markers in airway smooth muscle. Am J Physiol Cell Physiol 2007, 293:C429-C439.PubMedView Article
- Tran T, McNeill KD, Gerthoffer WT, Unruh H, Halayko AJ: Endogenous laminin is required for human airway smooth muscle cell maturation. Respir Res 2006, 7:117.PubMedView Article
- Dekkers BG, Schaafsma D, Tran T, Zaagsma J, Meurs H: Insulin-induced Laminin Expression Promotes a Hypercontractile Airway Smooth Muscle Phenotype. Am J Respir Cell Mol Biol 2009, 41:494–504.PubMedView Article
- Nguyen NM, Senior RM: Laminin isoforms and lung development: all isoforms are not equal. Dev Biol 2006, 294:271–279.PubMedView Article
- Virtanen I, Laitinen A, Tani T, Paakko P, Laitinen LA, Burgeson RE, Lehto VP: Differential expression of laminins and their integrin receptors in developing and adult human lung. Am J Respir Cell Mol Biol 1996, 15:184–196.PubMed
- Altraja A, Laitinen A, Virtanen I, Kampe M, Simonsson BG, Karlsson SE, Hakansson L, Venge P, Sillastu H, Laitinen LA: Expression of laminins in the airways in various types of asthmatic patients: a morphometric study. Am J Respir Cell Mol Biol 1996, 15:482–488.PubMed
- Amin K, Janson C, Seveus L, Miyazaki K, Virtanen I, Venge P: Uncoordinated production of Laminin-5 chains in airways epithelium of allergic asthmatics. Respir Res 2005, 6:110.PubMedView Article
- Schuger L, Skubitz AP, Zhang J, Sorokin L, He L: Laminin alpha1 chain synthesis in the mouse developing lung: requirement for epithelial-mesenchymal contact and possible role in bronchial smooth muscle development. J Cell Biol 1997, 139:553–562.PubMedView Article
- Relan NK, Yang Y, Beqaj S, Miner JH, Schuger L: Cell elongation induces laminin alpha2 chain expression in mouse embryonic mesenchymal cells: role in visceral myogenesis. J Cell Biol 1999, 147:1341–1350.PubMedView Article
- Hirst SJ, Twort CH, Lee TH: Differential effects of extracellular matrix proteins on human airway smooth muscle cell proliferation and phenotype. Am J Respir Cell Mol Biol 2000, 23:335–344.PubMed
- Dekkers BG, Bos IS, Gosens R, Halayko AJ, Zaagsma J, Meurs H: The Integrin-blocking Peptide RGDS Inhibits Airway Smooth Muscle Remodeling in a Guinea Pig Model of Allergic Asthma. Am J Respir Crit Care Med 2010, 181:556–565.PubMedView Article
- Plow EF, Haas TA, Zhang L, Loftus J, Smith JW: Ligand binding to integrins. J Biol Chem 2000, 275:21785–21788.PubMedView Article
- Aumailley M, Gerl M, Sonnenberg A, Deutzmann R, Timpl R: Identification of the Arg-Gly-Asp sequence in laminin A chain as a latent cell-binding site being exposed in fragment P1. FEBS Lett 1990, 262:82–86.PubMedView Article
- Graf J, Ogle RC, Robey FA, Sasaki M, Martin GR, Yamada Y, Kleinman HK: A pentapeptide from the laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor. Biochemistry 1987, 26:6896–6900.PubMedView Article
- Meurs H, Santing RE, Remie R, van der Mark TW, Westerhof FJ, Zuidhof AB, Bos IS, Zaagsma J: A guinea pig model of acute and chronic asthma using permanently instrumented and unrestrained animals. Nat Protoc 2006, 1:840–847.PubMedView Article
- Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J: Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007, 30:653–661.PubMedView Article
- Gosens R, Bos IS, Zaagsma J, Meurs H: Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005, 171:1096–1102.PubMedView Article
- Gosens R, Stelmack GL, Dueck G, McNeill KD, Yamasaki A, Gerthoffer WT, Unruh H, Gounni AS, Zaagsma J, Halayko AJ: Role of caveolin-1 in p42/p44 MAP kinase activation and proliferation of human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2006, 291:L523-L534.PubMedView Article
- Gosens R, Dueck G, Gerthoffer WT, Unruh H, Zaagsma J, Meurs H, Halayko AJ: p42/p44 MAP kinase activation is localized to caveolae-free membrane domains in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1163-L1172.PubMedView Article
- Gosens R, Dueck G, Rector E, Nunes RO, Gerthoffer WT, Unruh H, Zaagsma J, Meurs H, Halayko AJ: Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1348-L1358.PubMedView Article
- Jeffery PK: Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001, 164:S28-S38.PubMed
- Postma DS, Timens W: Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:434–439.PubMedView Article
- Graf J, Iwamoto Y, Sasaki M, Martin GR, Kleinman HK, Robey FA, Yamada Y: Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 1987, 48:989–996.PubMedView Article
- Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK: Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 1989, 58:933–943.PubMedView Article
- Ebina M, Takahashi T, Chiba T, Motomiya M: Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am Rev Respir Dis 1993, 148:720–726.PubMed
- Woodruff PG, Dolganov GM, Ferrando RE, Donnelly S, Hays SR, Solberg OD, Carter R, Wong HH, Cadbury PS, Fahy JV: Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 2004, 169:1001–1006.PubMedView Article
- Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M: Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003, 167:1360–1368.PubMedView Article
- Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare PD: Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol 1993, 74:2771–2781.PubMedView Article
- Oliver MN, Fabry B, Marinkovic A, Mijailovich SM, Butler JP, Fredberg JJ: Airway hyperresponsiveness, remodeling, and smooth muscle mass: right answer, wrong reason? Am J Respir Cell Mol Biol 2007, 37:264–272.PubMedView Article
- Matter ML, Laurie GW: A novel laminin E8 cell adhesion site required for lung alveolar formation in vitro. J Cell Biol 1994, 124:1083–1090.PubMedView Article
- Nelson J, McFerran NV, Pivato G, Chambers E, Doherty C, Steele D, Timson DJ: The 67 kDa laminin receptor: structure, function and role in disease. Biosci Rep 2008, 28:33–48.PubMedView Article
- Miyamoto S, Akiyama SK, Yamada KM: Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science 1995, 267:883–885.PubMedView Article
- Barthel SR, Johansson MW, McNamee DM, Mosher DF: Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol 2008, 83:1–12.PubMedView Article
- Georas SN, McIntyre BW, Ebisawa M, Bednarczyk JL, Sterbinsky SA, Schleimer RP, Bochner BS: Expression of a functional laminin receptor (alpha 6 beta 1, very late activation antigen-6) on human eosinophils. Blood 1993, 82:2872–2879.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.